TY - JOUR
T1 - Splenic artery embolization with Ankaferd blood stopper in a sheep model
AU - Koç, Osman
AU - Acar, Kadir
AU - Özbek, Orhan
AU - Güler, İbrahim
AU - Sarıtaş, Kadir
AU - Erdem, Tuba Bera
AU - Solak, Yalçın
AU - Toy, Hatice
AU - Küçükapan, Ahmet
AU - Özbek, Seda
AU - Gaipov, Abduzhappar
AU - Haznedaroğlu, İbrahim C.
N1 - Publisher Copyright:
© Turkish Society of Radiology 2016.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - PURPOSE Splenic artery embolization is a minimally invasive therapeutic procedure utilized in a number of disorders. Ankaferd blood stopper (ABS) is a novel hemostatic agent with a new mechanism of action independent of clotting factors. We aimed to investigate the safety and efficiency of ABS for splenic artery embolization in a sheep model. METHODS Seven adult female sheep were included in the study. Selective celiac angiography was performed using a 5F diagnostic catheter and then a 2.7F hydrophilic coating microcatheter was advanced coaxially to the distal part of the main splenic artery. Under fluoroscopic guidance, 6 mL mixture composed of half-and-half ABS and contrast agent was slowly injected. Fluoroscopy was used to observe the deceleration and stagnation of the flow. Control celiac angiograms were obtained immediately after the embolization. After the procedure, the animals were observed for one day and then sacrificed with intravenous sodium thiopental. RESULTS Technical success rate was 100%. None of the animals died or experienced a major systemic adverse event during the procedure. All of the spleens appeared dark on macroscopic examination due to excessive thrombosis. Microscopically, the majority of the splenic sinusoids (90%-95%) were necrotic. CONCLUSION In our study, splenic artery embolization by ABS was found to be safe and effective in the shortterm. Further studies are needed to better understand the embolizing potential of this novel hemostatic agent.
AB - PURPOSE Splenic artery embolization is a minimally invasive therapeutic procedure utilized in a number of disorders. Ankaferd blood stopper (ABS) is a novel hemostatic agent with a new mechanism of action independent of clotting factors. We aimed to investigate the safety and efficiency of ABS for splenic artery embolization in a sheep model. METHODS Seven adult female sheep were included in the study. Selective celiac angiography was performed using a 5F diagnostic catheter and then a 2.7F hydrophilic coating microcatheter was advanced coaxially to the distal part of the main splenic artery. Under fluoroscopic guidance, 6 mL mixture composed of half-and-half ABS and contrast agent was slowly injected. Fluoroscopy was used to observe the deceleration and stagnation of the flow. Control celiac angiograms were obtained immediately after the embolization. After the procedure, the animals were observed for one day and then sacrificed with intravenous sodium thiopental. RESULTS Technical success rate was 100%. None of the animals died or experienced a major systemic adverse event during the procedure. All of the spleens appeared dark on macroscopic examination due to excessive thrombosis. Microscopically, the majority of the splenic sinusoids (90%-95%) were necrotic. CONCLUSION In our study, splenic artery embolization by ABS was found to be safe and effective in the shortterm. Further studies are needed to better understand the embolizing potential of this novel hemostatic agent.
UR - http://www.scopus.com/inward/record.url?scp=84976612383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976612383&partnerID=8YFLogxK
U2 - 10.5152/dir.2015.15382
DO - 10.5152/dir.2015.15382
M3 - Article
C2 - 27306661
AN - SCOPUS:84976612383
VL - 22
SP - 354
EP - 357
JO - Diagnostic and Interventional Radiology
JF - Diagnostic and Interventional Radiology
SN - 1305-3825
IS - 4
ER -